コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ient population has the potential to improve transplant outcome.
2 or between histological arteriosclerosis and transplant outcome.
3 (c-statistics) were performed for models of transplant outcome.
4 D-induced obesity and its negative impact on transplant outcome.
5 hanisms by which these cells influence liver transplant outcome.
6 ng this disease-initiating process to modify transplant outcome.
7 s failing to be consistently associated with transplant outcome.
8 austion occurs and has a role in determining transplant outcome.
9 raft loss is not associated with poor second transplant outcome.
10 ry T cells (Tregs) play an important role in transplant outcome.
11 cs are becoming more important in predicting transplant outcome.
12 mpact of preoperative albumin levels on post-transplant outcome.
13 are therefore needed for improving long-term transplant outcome.
14 ere independently associated with successful transplant outcome.
15 ors other than islet quality that affect the transplant outcome.
16 tion of patients according to their risk for transplant outcome.
17 elsior (CS) solutions on islet isolation and transplant outcome.
18 er or surgeon transplant workload on corneal transplant outcome.
19 ector cells affect alloimmune reactivity and transplant outcome.
20 sociated with a detrimental effect on kidney transplant outcome.
21 oratory variables, to identify predictors of transplant outcome.
22 s for BK virus (BKV) replication may improve transplant outcome.
23 utic agents for the long-term improvement of transplant outcome.
24 ology of DC populations in relation to human transplant outcome.
25 ells in the complex events that affect liver transplant outcome.
26 arteriosclerosis, donor kidney discard, and transplant outcome.
27 ing regimen and source of stem cells, affect transplant outcome.
28 to identify indications, complications, and transplant outcome.
29 's would not appear to substantially improve transplant outcome.
30 nisms that are involved in determining islet transplant outcome.
31 matching at the triplet level affects kidney transplant outcome.
32 genetic variability in molecules relevant to transplant outcome.
33 ildren with ALL without compromising overall transplant outcome.
34 ersus-host disease (GVHD) and may compromise transplant outcome.
35 ted to improve unrelated donor selection and transplant outcome.
36 ne the influence of panresistant bacteria on transplant outcome.
37 s after brain death (DBD) donors on pancreas transplant outcome.
38 yte antigen loci is known to influence renal-transplant outcome.
39 e other emerging viruses that can affect the transplant outcome.
40 Donor hepatectomy time impairs liver transplant outcome.
41 unities to ultimately improve long-term lung transplant outcome.
42 risk of transplant or the combined death or transplant outcome.
43 ent travel distance was associated with lung transplant outcomes.
44 e novo DSA formation and potentially improve transplant outcomes.
45 invasive procedures and improves patient or transplant outcomes.
46 urce of HO-1 and higher levels improve renal transplant outcomes.
47 oholic steatohepatitis (NASH) with good post-transplant outcomes.
48 (HSPC) engraftment is paramount to improving transplant outcomes.
49 ues to lag behind the progress in short-term transplant outcomes.
50 t immunosuppression is known to affect renal transplant outcomes.
51 preservation fluids for liver allografts on transplant outcomes.
52 tin (EPO) is associated with improved kidney transplant outcomes.
53 transplantation is essential for successful transplant outcomes.
54 of antibody and B cells on acute and chronic transplant outcomes.
55 ion in a preparation may contribute to islet transplant outcomes.
56 h LN, income levels did not predict risk for transplant outcomes.
57 fact associated with adverse recipient post-transplant outcomes.
58 dels for reporting program-specific pancreas transplant outcomes.
59 while maintaining efficacy may improve renal transplant outcomes.
60 ould potentially lead to improved islet cell transplant outcomes.
61 nd improve risk assessment and prediction of transplant outcomes.
62 resistance, and risk prediction of pediatric transplant outcomes.
63 donor smoking history in relation to age on transplant outcomes.
64 es may interact to negatively influence lung transplant outcomes.
65 Little is known about their post-transplant outcomes.
66 ssociation of CAV2 gene variants with kidney transplant outcomes.
67 tment for known risk factors associated with transplant outcomes.
68 an important goal to improve long-term lung-transplant outcomes.
69 ransplantation has been associated with poor transplant outcomes.
70 rther assess the impact of EVLP on post-lung transplant outcomes.
71 dy mass index >=40 (severe obesity) on heart transplant outcomes.
72 between increasing center volume and cardiac transplant outcomes.
73 al agents or gene therapy to further improve transplant outcomes.
74 ditioning may not be required for successful transplant outcomes.
75 sensitization and adversely impacting islet transplant outcomes.
76 e impact of donor aged 70 years and older on transplant outcomes.
77 MF) is associated with good short-term renal transplant outcomes.
78 cal to the informed interpretation of kidney transplant outcomes.
79 environmental causes of disparities in renal transplant outcomes.
80 vidence shows their association with adverse transplant outcomes.
81 independent modifiable risk factor for renal transplant outcomes.
82 cific memory that can be targeted to improve transplant outcomes.
83 ncreased immunogenicity, thereby aggravating transplant outcomes.
84 -specific antibodies (DSA) against an RMM on transplant outcomes.
85 IRI) play a central role in alloimmunity and transplant outcomes.
86 r GDF15 for associations with patient kidney transplant outcomes.
87 obesity was not associated with adverse post-transplant outcomes.
88 prior to implantation that may improve post-transplant outcomes.
89 d potential as a cellular therapy to improve transplant outcomes.
90 es mellitus (DM) is said to adversely affect transplant outcomes.
91 f JCPyV infection and the donor's virome for transplant outcomes.
92 adult CHD transplant centers may have better transplant outcomes.
93 ions to protect the glycocalyx could improve transplant outcomes.
94 m to improve donor allograft procurement and transplant outcomes.
95 us cardiac arrest in DBD (caDBD) on pancreas transplant outcomes.
96 an is not stopped, thus resulting in optimal transplant outcomes.
97 ed eplet loads affect antibody responses and transplant outcomes.
98 week (UNOS-DGF), associates with poor kidney transplant outcomes.
99 esents a novel clinical target for improving transplant outcomes.
100 ith AKI are often discarded for fear of poor transplant outcomes.
101 care utilization or worse short or long-term transplant outcomes.
102 , and high levels correlated with poor islet transplant outcomes.
103 e, SOTR are at risk of nonadherence and poor transplant outcomes.
104 Vitamin A supplementation might improve transplant outcomes.
105 en virtual and actual crossmatch results and transplant outcomes.
106 toimmune disorder had no positive effects on transplant outcomes.
107 gens are important determinants of long-term transplant outcomes.
108 cant impact of these infections on the other transplant outcomes.
109 he factors that significantly affected early transplant outcome adversely within 3 months posttranspl
110 dentified a number of factors that influence transplant outcome after deceased heart beating donor ki
113 actors of sclerosis and its association with transplant outcomes among 977 consecutive patients treat
114 age on post-simultaneous liver-kidney (SLK) transplant outcomes among patients with CKD, leading som
115 rs for ZIKV infection among organ donors and transplant outcomes among recipients of donors with posi
116 aim of this study was to compare the kidney transplant outcomes among recipients of kidney after pri
117 lationship between microbial communities and transplant outcome and aid in assessing lung infections.
118 act of these leukocyte-directing proteins on transplant outcome and novel therapeutic approaches for
119 dom includes factors demonstrated to improve transplant outcome and promote equity in organ allocatio
120 ry donor-reactive T cells are detrimental to transplant outcome and that quantifying the frequency of
122 to confirm a relationship between post-heart transplant outcomes and center experience and to determi
123 significantly to the scientific analyses of transplant outcomes and complications and provide import
124 gradients may negatively impact other kidney transplant outcomes and could be used to identify patien
125 s a known risk factor associated with kidney transplant outcomes and is incorporated for determining
126 n humans, offering opportunities to optimize transplant outcomes and maximize donor organ utilization
130 urce of organs for transplantation with good transplant outcomes and there is scope for increasing th
131 ere are significant differences in both post-transplant outcomes and time to transplantation between
134 nd treatment of active CMV infection enhance transplant outcomes, and are the focus of this section.
135 existing literature on age-related changes, transplant outcomes, and complications in the elderly in
144 In children, poorly HLA-matched LD renal transplant outcomes are not inferior when compared with
147 with panresistant P. aeruginosa have similar transplant outcomes as patients with sensitive bacteria
150 onsidered as a possible prognostic factor in transplant outcomes, associated with anxiety, health-rel
154 e Index (KDPI), a metric intended to predict transplant outcomes based on donor characteristics but d
155 A similar decision model comparing kidney transplant outcomes before and after the introduction of
157 by facilitating viability testing, improving transplant outcome by early reversal of ischemia, and de
158 models were built to examine differences in transplant outcomes by graft type, adjusting for patient
159 that individual HLA loci play in determining transplant outcome can be achieved, and this is a major
160 ts demonstrates that excellent 5-year kidney transplant outcomes can be achieved without CNI drugs, w
164 rveillance biopsies and that correlates with transplant outcomes could be used to monitor KT recipien
165 tive of this study was to examine early lung transplant outcomes following EVLP using a large nationa
166 iopsy analysis is associated with acceptable transplant outcomes for elderly DCD kidneys and may incr
167 differences in access to transplant and post-transplant outcomes for ethnic minority patients in the
168 ize the relative lack of knowledge regarding transplant outcomes for infection-related corneal diseas
170 nsin (UW) preservation solutions in clinical transplant outcomes for liver, pancreas, and kidney tran
173 ver, few studies have examined how long-term transplant outcomes from older donors have evolved over
176 e candidate gene for association with kidney transplant outcomes given its proximity to CAV1 and its
178 ients from the multicenter, prospective Lung Transplant Outcomes Group cohort enrolled between July 2
182 pective cohort study of patients in the Lung Transplant Outcomes Group who underwent bilateral lung t
184 sttransplant anemia and its association with transplant outcomes have not been properly studied.
185 ct of donor-recipient sex matching on kidney transplant outcomes have reported heterogenous and confl
186 the most significant factor predicting poor transplant outcome (hazard ratio for 18-39 and 60+ years
188 s (DSAs) are associated with impaired kidney transplant outcome; however, whether these antibodies in
191 ship between donor hepatectomy time and post-transplant outcome in 12,974 recipients of deceased-dono
192 , its determinants, and the association with transplant outcome in a large cohort of transplanted chi
193 nt and donor age on immunoresponsiveness and transplant outcome in a uni- and multilateral cohort ana
195 e, is a significant predictor of unfavorable transplant outcome in first and second renal transplants
197 fect of donor age and cold ischaemic time on transplant outcome in kidneys donated after circulatory
198 etic polymorphisms have been associated with transplant outcome in some experimental and clinical stu
203 ts, but the influence of humoral immunity on transplant outcomes in children is not well understood.
205 yzed these parameters and compared them with transplant outcomes in NHP combined kidney and bone marr
206 factors of CMV disease and its impact on SPK transplant outcomes in recipients all receiving a consis
207 donor (D)/recipient (R) serostatus on kidney transplant outcomes in recipients who received CMV proph
208 ncome and racial/ethnic disparities on renal transplant outcomes in recipients with lupus nephritis (
209 emonstrate that mHGF markedly improves islet transplant outcomes in the highest preclinical species e
211 ntibody induction therapy for 6-month kidney transplant outcomes in the modern immunosuppression era.
212 nsplantation is already been used to monitor transplant outcomes in the United Kingdom and in the Uni
214 stigated the effect of smoking on postkidney transplant outcomes in the United States Renal Data Syst
217 the first time poorer waitlist and postliver transplant outcomes in young adults ages 18 to 24 years
219 al transplantation and critical appraisal of transplant outcomes including graft survival and patient
220 ased risk models associated with the risk of transplant outcomes including graft-versus-host disease
225 etween severity of chronic kidney injury and transplant outcome is similar for DCD and DBD kidneys.
228 ctors in modulating alloimmune responses and transplant outcomes is only now beginning to emerge.
235 ctive comparison of treatment-related kidney transplant outcomes may be facilitated by multivariable
237 cal care in the areas of donor use, clinical transplant outcomes, mechanisms of rejection, infectious
238 ating this into clinical practise to improve transplant outcome, much focus has been placed on trying
241 Until results from APOL1 Long-term Kidney Transplant Outcomes Network ancillary studies are availa
242 nor and recipient is associated with optimal transplant outcome, new information suggests that not ev
243 ialysis has been associated with poor kidney transplant outcome, no data about this association exist
244 re the main determinants of long-term kidney transplant outcome; nonimmunologic factors in isolation
245 pectively compared the transplantability and transplant outcome of two consecutive patient population
250 or and recipient had a significant effect on transplant outcome: older age was associated with increa
251 sed donor recovery, improvement of long-term transplant outcomes, optimization of immune monitoring,
252 xygen during preservation might improve post-transplant outcomes, particularly for kidneys subjected
253 nts, assess the impact of opioid use on post-transplant outcomes, present evidence supporting nonopio
256 A common lament is that long-term kidney transplant outcomes remain the same despite improvements
257 ease, with its associated morbidity and poor transplant outcome, represents a serious threat to trans
261 In conclusion, racial disparities in kidney transplant outcomes seem to persist even in a universal
263 m RDs who are not HLA-matched siblings, with transplant outcomes similar to patients with MSD grafts.
264 fied to determine how biological age impacts transplant outcome, such as age-related fibrosis or tubu
267 ed to identify new variables associated with transplant outcomes that are not currently collected by
268 as the MHC region as well as genomewide for transplant outcomes that span all solid organs, such as
269 erstand a differential effect of SES on post-transplant outcomes that was not seen during LVAD suppor
270 tem heparin administration improve DCD liver transplant outcomes, thus allowing for the most effectiv
271 ic murine model of diabetes by comparing the transplant outcomes to that of islets transplanted intra
272 e purpose of this study was to analyze renal transplant outcomes using this source of cadaveric (CAD)
276 Importantly, the predictive power for poorer transplant outcome was comparable for all definitions of
279 evelop a donor selection strategy to improve transplant outcome, we compared the contribution of thes
280 ence of B. cepacia complex genomovar type on transplant outcome, we undertook a retrospective study i
281 of donor-specific HLA antibodies (DSAs) and transplant outcomes, we conducted a cohort study that in
282 ith ESRD affects time to transplantation and transplant outcomes, we retrospectively analyzed 3782 ma
287 ed if their original consent forms to report transplant outcomes were not signed, if consent was with
291 nt studies have documented an improvement in transplant outcome when organs are preserved through pul
292 r (LD)-related risk factors affecting kidney transplant outcome will allow better donor selection and
293 est relative association measure for a heart transplant outcome with a risk factor was 8.6 (recipient
294 Mandatory continuous monitoring of early transplant outcome with centralized oversight was introd
295 tudy demonstrates significant improvement in transplant outcomes with donor grafts >=60-years old and
296 ion-controlled 1-g MMF results in comparable transplant outcomes with less GI toxicity during the fir
297 ion and sirolimus provides comparable 1-year transplant outcomes, with significantly better renal fun
298 se transplant model, we investigated whether transplant outcome would result in changes in the propor
299 ricans and that racial disparities in kidney transplant outcomes would be less pronounced among patie
300 which T cells are removed, it is likely that transplant outcomes would depend on which technique is u